DE69433687D1 - Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz - Google Patents

Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz

Info

Publication number
DE69433687D1
DE69433687D1 DE69433687T DE69433687T DE69433687D1 DE 69433687 D1 DE69433687 D1 DE 69433687D1 DE 69433687 T DE69433687 T DE 69433687T DE 69433687 T DE69433687 T DE 69433687T DE 69433687 D1 DE69433687 D1 DE 69433687D1
Authority
DE
Germany
Prior art keywords
growth hormone
dementia
medicine
manufacture
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433687T
Other languages
English (en)
Other versions
DE69433687T2 (de
Inventor
Bengt-Ake Bengtsson
Olle G P Isaksson
Jan-Ove Johansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAHLTECH I GOETEBORG GOETEB AB
Original Assignee
SAHLTECH I GOETEBORG GOETEB AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAHLTECH I GOETEBORG GOETEB AB filed Critical SAHLTECH I GOETEBORG GOETEB AB
Application granted granted Critical
Publication of DE69433687D1 publication Critical patent/DE69433687D1/de
Publication of DE69433687T2 publication Critical patent/DE69433687T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69433687T 1993-09-21 1994-09-21 Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz Expired - Lifetime DE69433687T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9303068A SE9303068D0 (sv) 1993-09-21 1993-09-21 New use
SE9303068 1993-09-21
PCT/SE1994/000875 WO1995008345A1 (en) 1993-09-21 1994-09-21 Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid

Publications (2)

Publication Number Publication Date
DE69433687D1 true DE69433687D1 (de) 2004-05-13
DE69433687T2 DE69433687T2 (de) 2005-03-17

Family

ID=20391162

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433687T Expired - Lifetime DE69433687T2 (de) 1993-09-21 1994-09-21 Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz

Country Status (13)

Country Link
US (1) US5736515A (de)
EP (1) EP0720483B1 (de)
JP (1) JPH09502973A (de)
AT (1) ATE263573T1 (de)
AU (1) AU683306B2 (de)
CA (1) CA2168570C (de)
DE (1) DE69433687T2 (de)
DK (1) DK0720483T3 (de)
ES (1) ES2218529T3 (de)
NZ (1) NZ274025A (de)
PT (1) PT720483E (de)
SE (1) SE9303068D0 (de)
WO (1) WO1995008345A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
JP2002524402A (ja) 1998-09-03 2002-08-06 ニューロンズ・リミテッド 神経保護
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
AU2003262552A1 (en) * 2003-07-29 2005-02-25 Ares Trading S.A. Use of human growth hormone in multiple system atrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2974088A (en) * 1958-07-18 1961-03-07 Merck & Co Inc Method of preparing growth hormone
US3118815A (en) * 1959-09-28 1964-01-21 Upjohn Co Growth hormone and recovery thereof
CA1224432A (en) * 1982-08-17 1987-07-21 Gary N. Buell Dna sequences, recombinant dna molecules and processes for producing bovine growth hormone-like polypeptides in high yield
US4521409A (en) * 1983-10-03 1985-06-04 Cornell Research Foundation, Inc. Use of growth hormone to enhance ruminant mammary development
JPS62500857A (ja) * 1985-01-28 1987-04-09 朴 承文 車輌の車輪点灯装置
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
CA1285874C (en) * 1985-08-23 1991-07-09 Thomas Harry Ferguson Injectable sustained release formulation
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
US4863736A (en) * 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
NZ223842A (en) * 1988-03-10 1991-07-26 Amgen Inc Porcine growth hormone analogues, production using genetic engineering and compositions for promoting growth in mammals

Also Published As

Publication number Publication date
DE69433687T2 (de) 2005-03-17
EP0720483A1 (de) 1996-07-10
NZ274025A (en) 2005-03-24
ATE263573T1 (de) 2004-04-15
SE9303068D0 (sv) 1993-09-21
CA2168570C (en) 2009-04-07
CA2168570A1 (en) 1995-03-30
ES2218529T3 (es) 2004-11-16
US5736515A (en) 1998-04-07
AU683306B2 (en) 1997-11-06
EP0720483B1 (de) 2004-04-07
WO1995008345A1 (en) 1995-03-30
AU7793394A (en) 1995-04-10
DK0720483T3 (da) 2004-08-09
JPH09502973A (ja) 1997-03-25
PT720483E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
DE69327402T2 (de) Vorbeugung und behandlung der peripheren neuropathie
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE68917219T2 (de) Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren.
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
DE69121715D1 (de) Die kombination des wachshormons und des insulin-ähnlichen wachstumsfaktors-i stimuliert das wachstum
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
PL320167A1 (en) 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity
SE8205244D0 (sv) Medel for avlegsnande av mikroorganismer fran vevnader
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
CA2074166A1 (en) Method for treating intestinal diseases
DE69314779T2 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
ATE98121T1 (de) Fettsaeuren zur behandlung und praevention von hautschaeden durch radiotherapie.
ATE159937T1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69023006T2 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE235237T1 (de) Sertralin zur behandlung von post-myocard-infarkt-patienten
HU901636D0 (en) Process for producing new benzothio-pyranyl-amines and pharmaceutical preparatives containing them as active substance
DE69627379D1 (de) Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
DE69124382T2 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69109293T2 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition